Omalizumab as a corticosteroid‐sparing agent in the treatment of bullous pemphigoid
Abstract Bullous pemphigoid (BP) is the most common autoimmune blistering skin disease, characterized by the development of autoantibodies against hemidesmosomal components BP180 and BP230. The mainstay of therapy is topical and systemic corticosteroids (CS) and immunosuppressors. As this pathology...
Gespeichert in:
| Hauptverfasser: | , , , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Wiley
2022-12-01
|
| Schriftenreihe: | Dermatologic Therapy |
| Schlagworte: | |
| Online-Zugang: | https://doi.org/10.1111/dth.15946 |
| Tags: |
Keine Tags, Fügen Sie das erste Tag hinzu!
|